Nuvalent, Inc.
NUVL
Κατάταξη σε μετοχές
#2112
Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to... Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering novel therapeutic solutions for individuals battling cancer. The company's pipeline features two prominent drug candidates. One of these is NVL-520, a highly selective ROS1 inhibitor capable of penetrating the brain. This compound is specifically designed to target ROS1 fusions that possess the normal ROS1 kinase domain, and crucially, it retains activity against mutations known to confer resistance to both approved and experimental ROS1 inhibitors. NVL-520 is currently undergoing Phase I clinical evaluation. Nuvalent's second key asset is NVL-655, an ALK-selective inhibitor that also exhibits brain-penetrant properties. This therapy seeks to address significant limitations of earlier generations of ALK inhibitors (first-, second-, and third-generation), including the development of treatment resistance, central nervous system-related adverse effects, and brain metastases. NVL-655 is presently being assessed in Phase I/II clinical trials. The company was established in 2017 and is based in Cambridge, Massachusetts.
Τιμή μετοχής
$123.96
Τελευταίος συγχρονισμός: 2026-07-21
Κεφαλαιοποίηση
$9.75B
Αλλαγή (1 ημέρα)
0.00%
Αλλαγή (1 έτος)
27.56%
Χώρα
US
Εμπόριο Nuvalent, Inc. (NUVL)
Κατηγορία
Healthcare
Δείκτης P/B για Nuvalent, Inc. (NUVL)
Δείκτης P/B στις October 2026 TTM: 8.30
Σύμφωνα με τις τελευταίες οικονομικές αναφορές και την τιμή μετοχής της Nuvalent, Inc., ο τρέχων δείκτης P/B (TTM) είναι 8.30. Στο τέλος του 2023, η εταιρεία είχε P/B δείκτη 6.12.
Ιστορικό P/B για την Nuvalent, Inc. από 2019 έως 2026
Δείκτης P/B στο τέλος κάθε έτους
| Έτος | Δείκτης P/B | Αλλαγή |
|---|---|---|
| 2026 (TTM) | 8.30 | 70.86% |
| 2024 | 4.86 | -20.55% |
| 2023 | 6.12 | 91.44% |
| 2022 | 3.19 | 119.56% |
| 2021 | 1.46 | -98.54% |
| 2020 | 99.44 | -289.54% |
| 2019 | -52.46 | 0.00% |
Δείκτης P/B για παρόμοιες εταιρείες ή ανταγωνιστές
| Εταιρεία | Δείκτης P/B | Διαφορά Δείκτη P/B | Χώρα |
|---|---|---|---|
| 6.251 | -24.72% |
US
|
|
| 13.2547 | 59.62% |
US
|
|
| 4.208 | -49.33% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -25.55% |
NL
|
